Denali Therapeutics Inc. (DNLI)
Largest Insider Buys in Sector
DNLI Stock Price History Chart
DNLI Stock Performance
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Activity of Denali Therapeutics Inc.
Over the last 12 months, insiders at Denali Therapeutics Inc. have bought $0 and sold $5.33M worth of Denali Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Denali Therapeutics Inc. have bought $0 and sold $88.04M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 550,000 shares for transaction amount of $9.9M was made by BRATTON DOUGLAS K (10 percent owner) on 2017‑12‑12.
List of Insider Buy and Sell Transactions, Denali Therapeutics Inc.
| 2024-06-06 | Sale | Cook Jennifer E. | director | 1,458 0.001% | $21.73 | $31,682 | +0.75% | |
| 2024-05-15 | Sale | SATO VICKI L | director | 1,674 0.0011% | $20.39 | $34,133 | -1.15% | |
| 2024-04-15 | Sale | SATO VICKI L | director | 1,666 0.0012% | $18.29 | $30,471 | +7.96% | |
| 2024-04-01 | Sale | Krognes Steve E. | director | 92,500 0.0663% | $20.50 | $1.9M | -6.57% | |
| 2024-03-15 | Sale | SATO VICKI L | director | 1,666 0.0012% | $20.10 | $33,487 | -3.68% | |
| 2024-02-15 | Sale | SATO VICKI L | director | 1,666 0.0012% | $18.37 | $30,604 | +7.73% | |
| 2024-02-14 | Sale | Schuth Alexander O. | COFO and Secretary | 20,128 0.0139% | $17.66 | $355,460 | +10.45% | |
| 2024-02-14 | Sale | Ho Carole | Chief Medical Officer | 1,405 0.001% | $17.79 | $24,995 | +10.45% | |
| 2024-02-13 | Sale | Watts Ryan J. | President and CEO | 9,589 0.0065% | $17.29 | $165,794 | +15.71% | |
| 2024-02-13 | Sale | Schuth Alexander O. | COFO and Secretary | 2,716 0.0018% | $17.29 | $46,960 | +15.71% | |
| 2024-02-13 | Sale | Ho Carole | Chief Medical Officer | 2,784 0.0019% | $17.29 | $48,135 | +15.71% | |
| 2024-02-13 | Sale | Krognes Steve E. | director | 2,750 0.0019% | $17.29 | $47,548 | +15.71% | |
| 2024-01-16 | Sale | SATO VICKI L | director | 1,666 0.0012% | $18.42 | $30,688 | +3.45% | |
| 2024-01-10 | Sale | Ho Carole | Chief Medical Officer | 4,668 0.0035% | $19.02 | $88,785 | +1.94% | |
| 2024-01-09 | Sale | Watts Ryan J. | President and CEO | 7,818 0.0057% | $19.78 | $154,640 | -4.25% | |
| 2024-01-05 | Sale | Watts Ryan J. | President and CEO | 17,483 0.0127% | $19.43 | $339,695 | -2.06% | |
| 2024-01-05 | Sale | Schuth Alexander O. | COFO and Secretary | 9,972 0.0072% | $19.43 | $193,756 | -2.06% | |
| 2024-01-05 | Sale | Ho Carole | Chief Medical Officer | 9,972 0.0072% | $19.43 | $193,756 | -2.06% | |
| 2024-01-05 | Sale | Krognes Steve E. | director | 3,208 0.0023% | $19.43 | $62,331 | -2.06% | |
| 2023-12-15 | Sale | SATO VICKI L | director | 1,666 0.0012% | $23.39 | $38,968 | -16.40% |
Insider Historical Profitability
| Watts Ryan J. | President and CEO | 238067 1.6414% | $22.00 | 0 | 61 | |
| Schuth Alexander O. | COFO and Secretary | 187341 0.3902% | $22.00 | 0 | 63 | |
| Ho Carole | Chief Medical Officer | 143605 0.1069% | $22.00 | 0 | 59 | |
| Krognes Steve E. | director | 47341 0.1032% | $22.00 | 0 | 18 | |
| SATO VICKI L | director | 116369 0.089% | $22.00 | 0 | 22 | |
| Cook Jennifer E. | director | 20038 0.0141% | $22.00 | 0 | 1 | |
| BRATTON DOUGLAS K | 10 percent owner | 9984836 7.2251% | $22.00 | 1 | 12 | <0.0001% |
| Tessier-Lavigne Marc | director | 1870356 1.3534% | $22.00 | 0 | 17 | |
| Schenkein David P | director | 0 0% | $22.00 | 0 | 4 |
Institutional Investor Ownership
| Baillie Gifford Co | $288.13M | 9.85 | 14.04M | -1.54% | -$4.5M | 0.22 | |
| BlackRock | $250.34M | 8.56 | 12.2M | +5.69% | +$13.47M | 0.01 | |
| The Vanguard Group | $225.07M | 7.69 | 10.97M | +1.24% | +$2.75M | <0.01 | |
| Wellington Management Company | $169.7M | 5.8 | 8.27M | +13.68% | +$20.42M | 0.03 | |
| State Street | $129.77M | 4.43 | 6.32M | +15.27% | +$17.19M | 0.01 | |
| Capital Research Global Investors | $124.15M | 4.24 | 6.05M | +107.94% | +$64.44M | 0.03 | |
| Temasek Holdings | $117.09M | 4 | 5.71M | -17.25% | -$24.41M | 0.65 | |
| Crestline Management Lp | $106.92M | 3.65 | 5.21M | -7.95% | -$9.23M | 10.13 | |
| Baker Bros Advisors LP | $76.57M | 2.62 | 3.73M | +43.13% | +$23.07M | 0.96 | |
| Geode Capital Management | $56.64M | 1.94 | 2.76M | +3.77% | +$2.06M | 0.01 | |
| Marshall Wace | $44.04M | 1.51 | 2.15M | +28.73% | +$9.83M | 0.06 | |
| BNY Mellon | $36.48M | 1.25 | 1.78M | -4.96% | -$1.9M | 0.01 | |
| T. Rowe Price | $32.72M | 1.12 | 1.59M | -38.07% | -$20.11M | <0.01 | |
| Credit Suisse | $32.14M | 1.1 | 1.57M | -0.63% | -$204,687.01 | 0.03 | |
| Camber Capital Management Lp | $30.78M | 1.05 | 1.5M | New | +$30.78M | 1.09 | |
| Citadel Advisors LLC | $28.01M | 0.96 | 1.37M | +1,904.15% | +$26.61M | 0.02 | |
| Flagship Pioneering | $28M | 0.96 | 1.36M | -41.18% | -$19.61M | 1.84 | |
| Dimensional Fund Advisors | $27.35M | 0.94 | 1.33M | +19.05% | +$4.38M | 0.01 | |
| Casdin Capital | $26.68M | 0.91 | 1.3M | 0% | +$0 | 1.99 | |
| Fidelity Investments | $25.29M | 0.86 | 1.23M | +92.08% | +$12.12M | <0.01 | |
| Gilder Gagnon Howe & Co. LLC | $24.07M | 0.82 | 1.17M | -3.82% | -$956,376.03 | 0.3 | |
| Yiheng Capital Llc | $23.61M | 0.81 | 1.15M | 0% | +$0 | 3.44 | |
| Northern Trust | $22.34M | 0.76 | 1.09M | -1.2% | -$270,166.32 | <0.01 | |
| Charles Schwab | $21.36M | 0.73 | 1.04M | +3.38% | +$698,952.25 | 0.01 | |
| Morgan Stanley | $19.05M | 0.65 | 928,126 | -5.05% | -$1.01M | <0.01 | |
| Goldman Sachs | $18.56M | 0.63 | 904,361 | +129.65% | +$10.48M | <0.01 | |
| Holocene Advisors, LP | $17.67M | 0.6 | 860,948 | New | +$17.67M | 0.07 | |
| Bank of America | $17.48M | 0.6 | 851,976 | +85.76% | +$8.07M | <0.01 | |
| Ubs Asset Management Americas Inc | $14.1M | 0.48 | 687,239 | -2.98% | -$432,972.05 | 0.01 | |
| Cercano Management Llc | $12.82M | 0.44 | 625,000 | 0% | +$0 | 0.36 | |
| Standard Life | $10.59M | 0.36 | 516,019 | +58.86% | +$3.92M | 0.02 | |
| Woodline Partners LP | $10.44M | 0.36 | 508,565 | +157.39% | +$6.38M | 0.1 | |
| Nuveen | $10.43M | 0.36 | 508,196 | +59.09% | +$3.87M | <0.01 | |
| Artal Group S A | $10.32M | 0.35 | 502,899 | -37.37% | -$6.16M | 0.06 | |
| T Rowe Price Investment Management Inc | $10.24M | 0.35 | 498,969 | 0% | +$0 | 0.01 | |
| Fisher Asset Management Llc | $9.63M | 0.33 | 469,169 | +17,066.81% | +$9.57M | <0.01 | |
| American Century Investments | $9.43M | 0.32 | 459,536 | -2.95% | -$286,418.17 | 0.01 | |
| Polar Capital | $9.29M | 0.32 | 452,669 | 0% | +$0 | 0.05 | |
| Candriam S C A | $9.19M | 0.31 | 447,878 | +25.15% | +$1.85M | 0.06 | |
| Rafferty Asset Management Llc | $8.92M | 0.31 | 434,909 | +35.08% | +$2.32M | 0.03 | |
| Wasatch Advisors | $8.26M | 0.28 | 402,670 | +28.94% | +$1.85M | 0.04 | |
| Clarius Group Llc | $8.05M | 0.28 | 392,218 | +3.69% | +$286,377.11 | 0.6 | |
| Millennium Management LLC | $8.02M | 0.27 | 390,616 | New | +$8.02M | 0.01 | |
| Citigroup | $7.85M | 0.27 | 382,416 | +170.69% | +$4.95M | 0.01 | |
| Arch Venture Management Llc | $7.82M | 0.27 | 381,249 | 0% | +$0 | 11.12 | |
| Artisan Partners | $7.51M | 0.26 | 365,832 | -4.72% | -$371,617.22 | 0.01 | |
| Balyasny Asset Management Llc | $7.45M | 0.26 | 363,027 | +39.31% | +$2.1M | 0.02 | |
| AXA | $7.4M | 0.25 | 360,808 | +0.06% | +$4,370.76 | 0.02 | |
| Ensign Peak Advisors Inc | $7.11M | 0.24 | 346,304 | -0.63% | -$45,000.36 | 0.01 | |
| UBS | $7.06M | 0.24 | 343,879 | +18.18% | +$1.09M | <0.01 |